APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Biosimilar Monoclonal Antibodies

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Selected research

Industry Growth & Trends

Global Biosimilar Monoclonal Antibodies Industry Growth and Trends Forecast to 2032

Report ID 173970940121 December 202593 pages

Choose your research edition.

Industry ResearchBiosimilar Monoclonal Antibodies Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Biosimilar Monoclonal Antibodies Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Biosimilar Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biosimilar Monoclonal Antibodies Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Biosimilar Monoclonal Antibodies Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Monoclonal antibodies (mAb) are antibodies produced by using identical immune cells that are clones of one unique parent cell. Since monoclonal antibodies are produced from clones of only one parent cell, all monoclonal antibodies produced by the parent cell are the same due to which, they are called biosimilar monoclonal antibodies.

Biosimilar Monoclonal Antibodies refer to the biologic medical product that are almost an identical copy of the original monoclonal antibodies but manufactured by a different company.

Global Biosimilar Monoclonal Antibodies key players include Celltrion, 3SBIO, Pfizer (Hospira), Novartis (Sandoz), etc. Global top four manufacturers hold a share nearly 85%.

Read the full market overview

Europe is the largest market, with a share about 40%, followed by China, and United States, both have a share about 50 percent.

In terms of product, Infliximab is the largest segment, with a share nearly 40%. And in terms of application, the largest application is Autoimmune Disease, followed by Oncology, etc.

Report Scope

This report provides a structured, data-driven view of the global Biosimilar Monoclonal Antibodies market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Biosimilar Monoclonal Antibodies market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Biosimilar Monoclonal Antibodies market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Biosimilar Monoclonal Antibodies.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Biosimilar Monoclonal Antibodies market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Biosimilar Monoclonal Antibodies Market by Company

Celltrion

Pfizer (Hospira)

3SBIO

Novartis (Sandoz)

Dr Reddy’s

Celgen Biopharma

Cadila Healthcare

Hisun Pharma

Torrent Pharmaceuticals

Biosimilar Monoclonal Antibodies Segment by Type

Infliximab

Rituximab

Trastuzumab

Adalimumab

Other

Biosimilar Monoclonal Antibodies Segment by Application

Oncology

Autoimmune Disease

Other

Biosimilar Monoclonal Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Monoclonal Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Biosimilar Monoclonal Antibodies manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Biosimilar Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Infliximab Table 2. Major Company of Rituximab Table 3. Major Company of Trastuzumab Table 4. Major Company of Adalimumab Table 5. Major Company of Other Table 6. Global Biosimilar Monoclonal Antibodies Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 8. Global Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Type (2021-2026) Table 9. Global Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (US$ Million) Table 10. Global Biosimilar Monoclonal Antibodies Sales Market Share in Value by Type (2021-2026) Table 11. Global Biosimilar Monoclonal Antibodies Price by Type (2021-2026) & (USD/Unit) Table 12. Global Biosimilar Monoclonal Antibodies Sales by Type (2027-2032) & (K Units) Table 13. Global Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Type (2027-2032) Table 14. Global Biosimilar Monoclonal Antibodies Sales by Type (2027-2032) & (US$ Million) Table 15. Global Biosimilar Monoclonal Antibodies Sales Market Share in Value by Type (2027-2032) Table 16. Global Biosimilar Monoclonal Antibodies Price by Type (2027-2032) & (USD/Unit) Table 17. North America Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 18. North America Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 20. Europe Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 24. Latin America Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Type (2021-2026) & (US$ Million) Table 27. Biosimilar Monoclonal Antibodies Industry Trends Table 28. Biosimilar Monoclonal Antibodies Industry Drivers Table 29. Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges Table 30. Biosimilar Monoclonal Antibodies Industry Restraints Table 31. Global Biosimilar Monoclonal Antibodies Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Company (2021-2026) Table 33. Global Biosimilar Monoclonal Antibodies Sales by Company (2021-2026) & (K Units) Table 34. Global Biosimilar Monoclonal Antibodies Sales Share by Company (2021-2026) Table 35. Global Biosimilar Monoclonal Antibodies Market Price by Company (2021-2026) & (USD/Unit) Table 36. Global Biosimilar Monoclonal Antibodies Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Biosimilar Monoclonal Antibodies Major Company Production Sites and Headquarters Table 38. Global Biosimilar Monoclonal Antibodies Company, Product Type & Application Table 39. Global Biosimilar Monoclonal Antibodies Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Biosimilar Monoclonal Antibodies by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Biosimilar Monoclonal Antibodies Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Biosimilar Monoclonal Antibodies Sales by Region (2021-2026) & (K Units) Table 44. Global Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Region (2021-2026) Table 45. Global Biosimilar Monoclonal Antibodies Sales by Region (2021-2026) & (US$ Million) Table 46. Global Biosimilar Monoclonal Antibodies Sales Market Share in Value by Region (2021-2026) Table 47. Global Biosimilar Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 48. Global Biosimilar Monoclonal Antibodies Sales by Region (2027-2032) & (K Units) Table 49. Global Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Region (2027-2032) Table 50. Global Biosimilar Monoclonal Antibodies Sales by Region (2027-2032) & (US$ Million) Table 51. Global Biosimilar Monoclonal Antibodies Sales Market Share in Value by Region (2027-2032) Table 52. Global Biosimilar Monoclonal Antibodies Sales (K Units), Value (US$ Million), Price (USD/Unit) and Gross Margin (2027-2032) Table 53. Global Biosimilar Monoclonal Antibodies Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 55. Global Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Application (2021-2026) Table 56. Global Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (US$ Million) Table 57. Global Biosimilar Monoclonal Antibodies Sales Market Share in Value by Application (2021-2026) Table 58. Global Biosimilar Monoclonal Antibodies Price by Application (2021-2026) & (USD/Unit) Table 59. Global Biosimilar Monoclonal Antibodies Sales by Application (2027-2032) & (K Units) Table 60. Global Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Application (2027-2032) Table 61. Global Biosimilar Monoclonal Antibodies Sales by Application (2027-2032) & (US$ Million) Table 62. Global Biosimilar Monoclonal Antibodies Sales Market Share in Value by Application (2027-2032) Table 63. Global Biosimilar Monoclonal Antibodies Price by Application (2027-2032) & (USD/Unit) Table 64. North America Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 65. North America Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 67. Europe Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 71. Latin America Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Application (2021-2026) & (US$ Million) Table 74. Celltrion Company Information Table 75. Celltrion Business Overview Table 76. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 77. Celltrion Biosimilar Monoclonal Antibodies Product Portfolio Table 78. Celltrion Recent Development Table 79. Pfizer (Hospira) Company Information Table 80. Pfizer (Hospira) Business Overview Table 81. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 82. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio Table 83. Pfizer (Hospira) Recent Development Table 84. 3SBIO Company Information Table 85. 3SBIO Business Overview Table 86. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 87. 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio Table 88. 3SBIO Recent Development Table 89. Novartis (Sandoz) Company Information Table 90. Novartis (Sandoz) Business Overview Table 91. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 92. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio Table 93. Novartis (Sandoz) Recent Development Table 94. Dr Reddy’s Company Information Table 95. Dr Reddy’s Business Overview Table 96. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 97. Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio Table 98. Dr Reddy’s Recent Development Table 99. Celgen Biopharma Company Information Table 100. Celgen Biopharma Business Overview Table 101. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 102. Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio Table 103. Celgen Biopharma Recent Development Table 104. Cadila Healthcare Company Information Table 105. Cadila Healthcare Business Overview Table 106. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 107. Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio Table 108. Cadila Healthcare Recent Development Table 109. Hisun Pharma Company Information Table 110. Hisun Pharma Business Overview Table 111. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 112. Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio Table 113. Hisun Pharma Recent Development Table 114. Torrent Pharmaceuticals Company Information Table 115. Torrent Pharmaceuticals Business Overview Table 116. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 117. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio Table 118. Torrent Pharmaceuticals Recent Development Table 119. North America Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 120. North America Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 121. North America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2026) Table 122. North America Biosimilar Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (K Units) Table 123. North America Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Country (2027-2032) Table 124. North America Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 125. North America Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 126. North America Biosimilar Monoclonal Antibodies Market Share by Country (2021-2026) Table 127. North America Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 128. North America Biosimilar Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 129. Europe Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 130. Europe Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 131. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2026) Table 132. Europe Biosimilar Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (K Units) Table 133. Europe Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Country (2027-2032) Table 134. Europe Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. Europe Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 136. Europe Biosimilar Monoclonal Antibodies Market Share by Country (2021-2026) Table 137. Europe Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. Europe Biosimilar Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 139. Asia-Pacific Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 140. Asia-Pacific Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 141. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2026) Table 142. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (K Units) Table 143. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Country (2027-2032) Table 144. Asia-Pacific Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Asia-Pacific Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 146. Asia-Pacific Biosimilar Monoclonal Antibodies Market Share by Country (2021-2026) Table 147. Asia-Pacific Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Asia-Pacific Biosimilar Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 149. Latin America Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 150. Latin America Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 151. Latin America Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2026) Table 152. Latin America Biosimilar Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (K Units) Table 153. Latin America Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Country (2027-2032) Table 154. Latin America Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 155. Latin America Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 156. Latin America Biosimilar Monoclonal Antibodies Market Share by Country (2021-2026) Table 157. Latin America Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 158. Latin America Biosimilar Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 159. Middle East and Africa Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 160. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 161. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share by Country (2021-2026) Table 162. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Forecast by Country (2027-2032) & (K Units) Table 163. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Country (2027-2032) Table 164. Middle East and Africa Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 165. Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026) & (US$ Million) Table 166. Middle East and Africa Biosimilar Monoclonal Antibodies Market Share by Country (2021-2026) Table 167. Middle East and Africa Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032) & (US$ Million) Table 168. Middle East and Africa Biosimilar Monoclonal Antibodies Market Share Forecast by Country (2027-2032) Table 169. Key Raw Materials Table 170. Raw Materials Key Suppliers Table 171. Biosimilar Monoclonal Antibodies Distributors List Table 172. Biosimilar Monoclonal Antibodies Customers List Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. Biosimilar Monoclonal Antibodies Image Figure 2. Global Biosimilar Monoclonal Antibodies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Biosimilar Monoclonal Antibodies Market Size (2021-2032) & (US$ Million) Figure 4. Global Biosimilar Monoclonal Antibodies Sales (2021-2032) & (K Units) Figure 5. Infliximab Image Figure 6. Global Infliximab Sales YoY Growth (2021-2032) & (K Units) Figure 7. Rituximab Image Figure 8. Global Rituximab Sales YoY Growth (2021-2032) & (K Units) Figure 9. Trastuzumab Image Figure 10. Global Trastuzumab Sales YoY Growth (2021-2032) & (K Units) Figure 11. Adalimumab Image Figure 12. Global Adalimumab Sales YoY Growth (2021-2032) & (K Units) Figure 13. Other Image Figure 14. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Biosimilar Monoclonal Antibodies Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Biosimilar Monoclonal Antibodies Market Share by Type 2025 VS 2032 Figure 17. North America Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Type in 2025 Figure 18. North America Biosimilar Monoclonal Antibodies Sales Market Share in Value by Type in 2025 Figure 19. Europe Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Type in 2025 Figure 20. Europe Biosimilar Monoclonal Antibodies Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Market Share in Value by Type in 2025 Figure 23. Latin America Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Biosimilar Monoclonal Antibodies Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Biosimilar Monoclonal Antibodies Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Oncology Image Figure 30. Global Oncology Sales YoY Growth (2021-2032) & (K Units) Figure 31. Autoimmune Disease Image Figure 32. Global Autoimmune Disease Sales YoY Growth (2021-2032) & (K Units) Figure 33. Other Image Figure 34. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Biosimilar Monoclonal Antibodies Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Biosimilar Monoclonal Antibodies Market Share by Application 2025 VS 2032 Figure 37. North America Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Application in 2025 Figure 38. North America Biosimilar Monoclonal Antibodies Sales Market Share in Value by Application in 2025 Figure 39. Europe Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Application in 2025 Figure 40. Europe Biosimilar Monoclonal Antibodies Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Market Share in Value by Application in 2025 Figure 43. Latin America Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Biosimilar Monoclonal Antibodies Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Market Share in Value by Application in 2025 Figure 47. North America Biosimilar Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Biosimilar Monoclonal Antibodies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Biosimilar Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Biosimilar Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Biosimilar Monoclonal Antibodies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Biosimilar Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Biosimilar Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Biosimilar Monoclonal Antibodies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Biosimilar Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Biosimilar Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Biosimilar Monoclonal Antibodies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Biosimilar Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Biosimilar Monoclonal Antibodies Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Biosimilar Monoclonal Antibodies Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Biosimilar Monoclonal Antibodies Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Biosimilar Monoclonal Antibodies Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Infliximab
  • Rituximab
  • Trastuzumab
  • Adalimumab
  • Other
Applications
  • Oncology
  • Autoimmune Disease
  • Other
Companies covered
  • Celltrion
  • Pfizer (Hospira)
  • 3SBIO
  • Novartis (Sandoz)
  • Dr Reddy’s
  • Celgen Biopharma
  • Cadila Healthcare
  • Hisun Pharma
  • Torrent Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Biosimilar Monoclonal Antibodies Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Biosimilar Monoclonal Antibodies Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Biosimilar Monoclonal Antibodies Market by Type
  6. 1.3.1 Infliximab
  7. 1.3.2 Rituximab
  8. 1.3.3 Trastuzumab
  9. 1.3.4 Adalimumab
  10. 1.3.5 Other
  11. 1.4 Global Biosimilar Monoclonal Antibodies Market Size by Type
  12. 1.4.1 Global Biosimilar Monoclonal Antibodies Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Biosimilar Monoclonal Antibodies Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Biosimilar Monoclonal Antibodies Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Biosimilar Monoclonal Antibodies Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Biosimilar Monoclonal Antibodies Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Biosimilar Monoclonal Antibodies Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Biosimilar Monoclonal Antibodies Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Biosimilar Monoclonal Antibodies Industry Trends
  2. 2.2 Biosimilar Monoclonal Antibodies Industry Drivers
  3. 2.3 Biosimilar Monoclonal Antibodies Industry Opportunities and Challenges
  4. 2.4 Biosimilar Monoclonal Antibodies Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Biosimilar Monoclonal Antibodies Revenue (2021-2026)
  2. 3.2 Global Top Players by Biosimilar Monoclonal Antibodies Sales (2021-2026)
  3. 3.3 Global Top Players by Biosimilar Monoclonal Antibodies Price (2021-2026)
  4. 3.4 Global Biosimilar Monoclonal Antibodies Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Biosimilar Monoclonal Antibodies Major Company Production Sites & Headquarters
  6. 3.6 Global Biosimilar Monoclonal Antibodies Company, Product Type & Application
  7. 3.7 Global Biosimilar Monoclonal Antibodies Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Biosimilar Monoclonal Antibodies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Biosimilar Monoclonal Antibodies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Biosimilar Monoclonal Antibodies Tier 1, Tier 2, and Tier 3
4 Biosimilar Monoclonal Antibodies Regional Status and Outlook
  1. 4.1 Global Biosimilar Monoclonal Antibodies Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Biosimilar Monoclonal Antibodies Historic Market Size by Region
  3. 4.2.1 Global Biosimilar Monoclonal Antibodies Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Biosimilar Monoclonal Antibodies Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Biosimilar Monoclonal Antibodies Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Biosimilar Monoclonal Antibodies Forecasted Market Size by Region
  7. 4.3.1 Global Biosimilar Monoclonal Antibodies Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Biosimilar Monoclonal Antibodies Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Biosimilar Monoclonal Antibodies Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Biosimilar Monoclonal Antibodies by Application
  1. 5.1 Biosimilar Monoclonal Antibodies Market by Application
  2. 5.1.1 Oncology
  3. 5.1.2 Autoimmune Disease
  4. 5.1.3 Other
  5. 5.2 Global Biosimilar Monoclonal Antibodies Market Size by Application
  6. 5.2.1 Global Biosimilar Monoclonal Antibodies Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Biosimilar Monoclonal Antibodies Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Biosimilar Monoclonal Antibodies Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Biosimilar Monoclonal Antibodies Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Biosimilar Monoclonal Antibodies Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Biosimilar Monoclonal Antibodies Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Biosimilar Monoclonal Antibodies Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Celltrion
  2. 6.1.1 Celltrion Company Information
  3. 6.1.2 Celltrion Business Overview
  4. 6.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Celltrion Biosimilar Monoclonal Antibodies Product Portfolio
  6. 6.1.5 Celltrion Recent Developments
  7. 6.2 Pfizer (Hospira)
  8. 6.2.1 Pfizer (Hospira) Company Information
  9. 6.2.2 Pfizer (Hospira) Business Overview
  10. 6.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Portfolio
  12. 6.2.5 Pfizer (Hospira) Recent Developments
  13. 6.3 3SBIO
  14. 6.3.1 3SBIO Company Information
  15. 6.3.2 3SBIO Business Overview
  16. 6.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 3SBIO Biosimilar Monoclonal Antibodies Product Portfolio
  18. 6.3.5 3SBIO Recent Developments
  19. 6.4 Novartis (Sandoz)
  20. 6.4.1 Novartis (Sandoz) Company Information
  21. 6.4.2 Novartis (Sandoz) Business Overview
  22. 6.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Portfolio
  24. 6.4.5 Novartis (Sandoz) Recent Developments
  25. 6.5 Dr Reddy’s
  26. 6.5.1 Dr Reddy’s Company Information
  27. 6.5.2 Dr Reddy’s Business Overview
  28. 6.5.3 Dr Reddy’s Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Dr Reddy’s Biosimilar Monoclonal Antibodies Product Portfolio
  30. 6.5.5 Dr Reddy’s Recent Developments
  31. 6.6 Celgen Biopharma
  32. 6.6.1 Celgen Biopharma Company Information
  33. 6.6.2 Celgen Biopharma Business Overview
  34. 6.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Portfolio
  36. 6.6.5 Celgen Biopharma Recent Developments
  37. 6.7 Cadila Healthcare
  38. 6.7.1 Cadila Healthcare Company Information
  39. 6.7.2 Cadila Healthcare Business Overview
  40. 6.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Portfolio
  42. 6.7.5 Cadila Healthcare Recent Developments
  43. 6.8 Hisun Pharma
  44. 6.8.1 Hisun Pharma Company Information
  45. 6.8.2 Hisun Pharma Business Overview
  46. 6.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Hisun Pharma Biosimilar Monoclonal Antibodies Product Portfolio
  48. 6.8.5 Hisun Pharma Recent Developments
  49. 6.9 Torrent Pharmaceuticals
  50. 6.9.1 Torrent Pharmaceuticals Company Information
  51. 6.9.2 Torrent Pharmaceuticals Business Overview
  52. 6.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Portfolio
  54. 6.9.5 Torrent Pharmaceuticals Recent Developments
7 North America by Country
  1. 7.1 North America Biosimilar Monoclonal Antibodies Sales by Country
  2. 7.1.1 North America Biosimilar Monoclonal Antibodies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Biosimilar Monoclonal Antibodies Sales by Country (2021-2026)
  4. 7.1.3 North America Biosimilar Monoclonal Antibodies Sales Forecast by Country (2027-2032)
  5. 7.2 North America Biosimilar Monoclonal Antibodies Market Size by Country
  6. 7.2.1 North America Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
  8. 7.2.3 North America Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Biosimilar Monoclonal Antibodies Sales by Country
  2. 8.1.1 Europe Biosimilar Monoclonal Antibodies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Biosimilar Monoclonal Antibodies Sales by Country (2021-2026)
  4. 8.1.3 Europe Biosimilar Monoclonal Antibodies Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Biosimilar Monoclonal Antibodies Market Size by Country
  6. 8.2.1 Europe Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
  8. 8.2.3 Europe Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales by Country
  2. 9.1.1 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Biosimilar Monoclonal Antibodies Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Biosimilar Monoclonal Antibodies Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Biosimilar Monoclonal Antibodies Market Size by Country
  6. 9.2.1 Asia-Pacific Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Biosimilar Monoclonal Antibodies Sales by Country
  2. 10.1.1 South America Biosimilar Monoclonal Antibodies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Biosimilar Monoclonal Antibodies Sales by Country (2021-2026)
  4. 10.1.3 South America Biosimilar Monoclonal Antibodies Sales Forecast by Country (2027-2032)
  5. 10.2 South America Biosimilar Monoclonal Antibodies Market Size by Country
  6. 10.2.1 South America Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
  8. 10.2.3 South America Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country
  2. 11.1.1 Middle East and Africa Biosimilar Monoclonal Antibodies Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Biosimilar Monoclonal Antibodies Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Biosimilar Monoclonal Antibodies Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country
  6. 11.2.1 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Biosimilar Monoclonal Antibodies Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Biosimilar Monoclonal Antibodies Value Chain Analysis
  2. 12.1.1 Biosimilar Monoclonal Antibodies Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Biosimilar Monoclonal Antibodies Production Mode & Process
  7. 12.2 Biosimilar Monoclonal Antibodies Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Biosimilar Monoclonal Antibodies Distributors
  10. 12.2.3 Biosimilar Monoclonal Antibodies Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst